BIOMARKER STUDIES AND THE FUTURE OF PERSONALIZED TREATMENT FOR DEPRESSION

WHAT IS THE THRESHOLD FOR A CLINICALLY RELEVANT EFFECT? THE CASE OF MAJOR DEPRESSIVE DISORDERS

(2014) Pim Cuijpers et al.   DEPRESSION AND ANXIETY

Genetic susceptibility for bipolar disorder and response to antidepressants in major depressive disorder

(2013) Katherine E. Tansey et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS

Discovering, comparing, and combining moderators of treatment on outcome after randomized clinical trials: a parametric approach

(2013) Helena Chmura Kraemer   STATISTICS IN MEDICINE

The Canadian Biomarker Integration Network in Depression (CAN-BIND): Advances in Response Prediction

(2012) Sidney H. Kennedy et al.   CURRENT PHARMACEUTICAL DESIGN

Biomarkers predicting treatment outcome in depression: what is clinically significant?

(2012) Rudolf Uher et al.   PHARMACOGENOMICS

International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol

(2011) Leanne M Williams et al.   Trials

Genome-Wide Pharmacogenetics of Antidepressant Response in the GENDEP Project

(2010) Rudolf Uher et al.   AMERICAN JOURNAL OF PSYCHIATRY

Research Domain Criteria (RDoC): Toward a New Classification Framework for Research on Mental Disorders

(2010) Thomas Insel et al.   AMERICAN JOURNAL OF PSYCHIATRY

Selecting Among Second-Step Antidepressant Medication Monotherapies

(2008) A. John Rush et al.   ARCHIVES OF GENERAL PSYCHIATRY